How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,040 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Oxycodone abuse in New York City: Characteristics of intravenous and intranasal users (PubMed)

Oxycodone abuse in New York City: Characteristics of intravenous and intranasal users This pilot study sought to characterize typical nonmedical oxycodone use in the New York Metropolitan area. Accordingly, a clinical interview was administered to 25 intranasal (IN) and 25 intravenous (IV) oxycodone abusers to capture demographics and patterns of use within the region. IN and IV abusers shared a number of similar characteristics including age, proportion of men and women, criminal history, drug (...) use history, and current recreational drug use. However, the two populations also differed in a number of aspects. IV oxycodone users had lower rates of employment, earlier onset of illicit drug use, and more current heroin use. Although IN users reported somewhat more frequent use of oxycodone weekly, IV users were more likely to supplement their oxycodone use with other opioid drugs, most notably heroin. Additional research is needed to confirm these observed differences, yet these data may

Full Text available with Trip Pro

2011 The American Journal on Addictions

162. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics

Treatment /economics /methods; Quality-Adjusted Life Years; Substance Abuse, Intravenous /complications /epidemiology; Vietnam /epidemiology AccessionNumber 22012014798 Date bibliographic record published 27/06/2012 Date abstract record published 05/02/2013 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print PubMed record Original research Share Message for NHS EED database users (...) Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics Tran BX, Ohinmaa A, Duong

2013 NHS Economic Evaluation Database.

163. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. (PubMed)

Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Opioid analgesics can be abused by crushing followed by solubilization and intravenous injection to attain rapid absorption. Morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA, MS-sNT), indicated for management of chronic, moderate to severe pain, contain pellets of morphine sulfate with a sequestered naltrexone (...) core. Should product tampering by crushing occur, the sequestered naltrexone is intended for release to reduce morphine-induced subjective effects.This study compared self-reports of high, euphoria, and drug-liking effects of intravenous morphine alone versus intravenous morphine combined with naltrexone in a clinical simulation of intravenous abuse of crushed MS-sNT.This single-center, randomized, double-blind, crossover study characterized subjective effects of naltrexone administered

Full Text available with Trip Pro

2011 Drugs in R&D Controlled trial quality: predicted high

164. Hepatitis C in Injection-Drug Users — A Hidden Danger of the Opioid Epidemic (PubMed)

Analgesics, Opioid Drug Users Epidemics Hepatitis C etiology Humans Opioid-Related Disorders complications epidemiology Substance Abuse, Intravenous complications 2018 3 31 6 0 2018 3 31 6 0 2018 6 21 6 0 ppublish 29601263 10.1056/NEJMp1716871 PMC5993680 NIHMS972424 JAMA. 2016 Jul 12;316(2):191-210 27404187 Drug Alcohol Depend. 2017 Feb 1;171:39-49 28013096 MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):470-473 28493860 Am J Public Health. 2018 Feb;108(2):175-181 29267061 Lancet Gastroenterol Hepatol (...) Hepatitis C in Injection-Drug Users — A Hidden Danger of the Opioid Epidemic 29601263 2018 06 20 2018 11 14 1533-4406 378 13 2018 03 29 The New England journal of medicine N. Engl. J. Med. Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic. 1169-1171 10.1056/NEJMp1716871 Liang T Jake TJ From the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (T.J.L.); and the Centers for Disease Control and Prevention

Full Text available with Trip Pro

2018 The New England journal of medicine

165. A Plea for Harm Reduction Policing Involving People Who Use Drugs (PubMed)

, Canada. Bird Lorna L Vancouver Area Network of Drug Users, Vancouver, BC, Canada. Sex Workers United Against Violence, Vancouver, BC, Canada. eng Letter 2018 04 08 Iran Int J Health Policy Manag 101619905 2322-5939 0 Analgesics, Opioid H IM Analgesics, Opioid administration & dosage adverse effects Crime Delivery of Health Care Drug Overdose Drug Users Harm Reduction Humans Law Enforcement Police Public Policy Substance Abuse, Intravenous Substance-Related Disorders therapy 2018 12 22 2018 03 17 2018 (...) A Plea for Harm Reduction Policing Involving People Who Use Drugs 30078300 2018 11 26 2018 11 26 2322-5939 7 8 2018 04 08 International journal of health policy and management Int J Health Policy Manag A Plea for Harm Reduction Policing Involving People Who Use Drugs. 766-767 10.15171/ijhpm.2018.29 Jozaghi Ehsan E The British Columbia Centre for Disease Control, Vancouver, BC, Canada. The School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC

Full Text available with Trip Pro

2018 International journal of health policy and management

166. Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use

Intervention/treatment Phase Substance Abuse, Intravenous Prevention and Control Behavioral: Break the Cycle Intervention Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 400 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Other Official Title: Break the Cycle: Adapting Break the Cycle to Reduce Initiation Into Injecting Drug Use in Tallinn, Estonia and New York City (...) : GCO 15-1445 First Posted: April 18, 2018 Last Update Posted: May 24, 2018 Last Verified: May 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Substance-Related Disorders Substance Abuse, Intravenous Chemically-Induced Disorders Mental Disorders

2018 Clinical Trials

167. An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

tuberculosis, osteoarthritic tuberculosis, tuberculosis meningitis), as judged by the Investigator. Corrected QT Interval > 450 milliseconds. History of allergy to any of the trial investigational product/s or related substances as confirmed by the clinical judgement of the Investigator. History of photosensitivity. Known or suspected, current or history of within the past 2 years, alcohol or drug abuse, that is, in the opinion of the Investigator, sufficient to compromise the safety or cooperation (...) An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

168. A Study to Evaluate the Safety, Tolerability and Study Drug Absorption to the Blood After Administration of Single Ascending Doses of AZD8154 in Healthy Participants.

(e.g., rapamycin, everolimus) or PI3K inhibitor (selective or non-selective PI3K inhibitors). Known or suspected history of drug abuse as judged by the Investigator. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months. History of alcohol abuse or excessive intake of alcohol as judged by the Investigator. Positive screen for drugs of abuse or cotinine (nicotine) at the Screening Visit or admission to the Clinical Unit or positive (...) A Study to Evaluate the Safety, Tolerability and Study Drug Absorption to the Blood After Administration of Single Ascending Doses of AZD8154 in Healthy Participants. A Study to Evaluate the Safety, Tolerability and Study Drug Absorption to the Blood After Administration of Single Ascending Doses of AZD8154 in Healthy Participants. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms

2018 Clinical Trials

169. Drug Interaction Study of CT1812 in Healthy Volunteers

therapy within 2 weeks prior to administration of the first dose of any study-related treatment. This exclusion is extended to 4 weeks for any drugs known to induce or inhibit hepatic drug metabolism. Consumption of alcohol within 14 days prior to dose administration or during any in-patient period A positive urine drug screen including ethanol, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and opiates Any history of alcohol abuse, illicit drug use, significant mental illness, physical (...) dependence to any opioid within the past two years, or any history of drug abuse or addiction within the past two years A history of difficulty with donating blood Donated whole blood within 45 days or blood products within 7 days prior to enrollment. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2018 Clinical Trials

170. Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

), during the 7 days before the first dose of trial medication. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before first admission to this study; in the follow-up period of another clinical trial at the time of screening for this study. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly. Blood pressure and heart rate in supine position at the screening examination outside (...) the ranges: blood pressure 100-140 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 45_90 beats/min, unless judged not clinically significant. Possibility that the volunteer will not cooperate with the requirements of the protocol. Evidence of drug abuse on urine testing. Positive test for hepatitis B, hepatitis C or HIV. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor. Objection by General Practitioner (GP) to volunteer entering trial. Contacts and Locations Go

2018 Clinical Trials

171. A Comparison of How Likely it is That Different Tablets of Oxycodone Will be Broken up and Snorted by Adults Who Sometimes Take Drugs for Pleasure

examination, 12-lead ECG (relevant QTcF prolongation, i.e., QTcF above 450 milliseconds); other safety parameters. Blood loss of 100 milliliters or more since enrollment in this trial (excluding blood taken for this trial). For female participants: positive or missing pregnancy test. Positive or missing alcohol test or urine test for drugs of abuse (except for cannabinoids). Any hint, especially intravenous or intranasal, of chronic drug abuse, e.g., injection site (not related to trial procedures (...) IMPs must be insufflated in the following pre-defined order. Oxycodone API or placebo to match oxycodone API must always be insufflated first. Oxycodone immediate release (IR) abuse-deterrent formulation (ADF) or placebo to match oxycodone IR ADF must always be insufflated second. The total mass of each single dose of treatment will be 570 milligrams. Condition or disease Intervention/treatment Phase Substance Abuse Drug: Oxycodone IR ADF Drug: Oxycodone API powder Drug: Placebo to match oxycodone

2018 Clinical Trials

172. Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

-generation EGFR-TKIs resistance along with T790M negative. Condition or disease Intervention/treatment Phase Carcinoma Non-small Cell Lung Cancer Lung Neoplasm Biological: Sintilimab Drug: Anlotinib Hydrochloride Phase 2 Detailed Description: Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1, Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD.The primary hypothesis of this study is that participants will have a longer (...) -generation EGFR-TKIs Drug Resistance Along With T790M Negative NSCLC Actual Study Start Date : November 20, 2018 Estimated Primary Completion Date : December 31, 2019 Estimated Study Completion Date : December 31, 2021 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Anlotinib Hydrochloride+Sintilimab Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each

2018 Clinical Trials

173. Naloxone for Respiratory Depression in Patients with Drug or Addiction Issues: A Review of the Evidence on Safety and Guidelines

Naloxone for Respiratory Depression in Patients with Drug or Addiction Issues: A Review of the Evidence on Safety and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all (...) , provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Naloxone for Respiratory Depression in Patients with Drug or Addiction Issues: A Review of the Evidence on Safety and Guidelines DATE: 05 September 2012 CONTEXT AND POLICY ISSUES Natural or synthetic

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

174. Suboxone for Drug Detoxification: Clinical Effectiveness and Guidelines

/pmc/articles/PMC2610690 PubMed: PM18984887 5. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction [Internet]. 2005 Aug [cited 2012 Aug 16];100(8):1090-100. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1480367 PubMed: PM16042639 Non-Randomized Studies 6. Mckeganey N, Russell C (...) , Cockayne L. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. J Subst Abuse Treat. 2012 Jun 15. Epub ahead of print. PubMed: PM22703715 Suboxone for Drug Detoxification 3 7. Steele A, Cunningham P. A comparison of Suboxone and clonidine treatment outcomes in opiate detoxification. Arch Psychiatr Nurs. 2012 Aug;26(4):316-23. PubMed: PM22835751 8. Rapeli P, Fabritius C, Alho H, Salaspuro M

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

175. Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty

Sponsor: Duke University Information provided by (Responsible Party): Duke University Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if intravenous acetaminophen is superior to oral acetaminophen when used as part of a multimodal pathway for primary total hip arthroplasty. Condition or disease Intervention/treatment Phase Osteoarthritis Acetaminophen Arthroplasty, Hip Replacement Drug: Intravenous acetaminophen Drug: Oral acetaminophen Phase 4 Detailed (...) Description: This is a single center, prospective, randomized controlled study. 60 subjects will be recruited (see #6 Recruitment and Compensation below). On the day of surgery, subjects will be randomized to receive either the study intervention (intravenous acetaminophen and placebo tablets) or the control intervention (intravenous saline and active acetaminophen tablets). The Investigational Drug Service will prepare each intervention package, which will include one intravenous and one oral medication

2016 Clinical Trials

176. Intravenous Dexamethasone for Ropivacaine Axillary Block

Universitaire de Besancon Study Details Study Description Go to Brief Summary: Prospective monocentric double-blind controlled randomised trial Aim is to assess prolonged postsurgical analgesia by intravenous dexamethasone versus intravenous placebo, after ultrasound guided axillary brachial plexus block Condition or disease Intervention/treatment Phase Postoperative Pain Anesthesia Forearm Injuries Drug: intravenous dexamethasone Drug: intravenous placebo Drug: perineural ropivacaine Other: ultrasound (...) Start Date : December 1, 2016 Actual Primary Completion Date : March 16, 2017 Actual Study Completion Date : September 16, 2017 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: intravenous dexamethasone intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia Drug: intravenous dexamethasone intravenous injection of dexamethasone Other Name: DEXAMETHASONE MYLAN code UCD 9223084

2016 Clinical Trials

177. Comparison of Two Intravenous Lipid Emulsions in Home Parenteral Nutrition Patients

and expected to require long-term PN for at least 13 more months Exclusion Criteria: Subjects not already on Intralipid PN Inability to give informed consent Alcohol or drug abuse Pregnant and lactating women Clinical instability such as the following: Acute pulmonary edema Decompensated heart failure Decompensated chronic liver disease Severe post-traumatic conditions Uncontrolled diabetes mellitus Acute myocardial infarction Acute stroke Acute thromboembolism Metabolic acidosis Sepsis Hypotonic (...) Comparison of Two Intravenous Lipid Emulsions in Home Parenteral Nutrition Patients Comparison of Two Intravenous Lipid Emulsions in Home Parenteral Nutrition Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2016 Clinical Trials

178. Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease

hematoma, hydrocephalus and structural brain lesions, drug addiction, alcoholism, substance abuse, thyroid disease, parathyroid disease, vitamins and other nutritional deficiencies and vascular etc.] Subject with vascular dementia as determined by the clinical criteria of DSM-IV and the imaging criteria of Erkinkuntii Subject with severe white matter hyperintensities (i.e. ≥ 25mm of the deep white matter and ≥ 10mm of the periventricular capping/banding in lengths) Abnormal laboratory findings (...) of the following methods Use a condom Use of contraceptive (oral, dermal, or injectable) Use an intra-uterine contraceptive device Subjects with a history of alcohol abuse (>30g/day) or drug abuse Subjects who cannot undergo any of the tests performed in this clinical trial (for example, MRI, CT, PET, CSF study) Subjects with known allergies to protein products (Bovine serum), antibiotics (gentamycin) or DMSO Subjects whom the principal investigator considers inappropriate for participation in theis study

2016 Clinical Trials

179. Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair

anti oxidant action, and fewer side effects. However, there is no report about the analgesic effect of vitamin C after arthroscopic rotator cuff repair. The purpose of this trial was to compare the effects of a intravenous vitamin C injection on postoperative pain and opioid consumption versus non-treated group after arthroscopic rotator cuff repair. Condition or disease Intervention/treatment Phase Rotator Cuff Tear Drug: Intravenous Nutrition (Vitamins) injection Drug: Intravenous Saline (...) Primary Completion Date : May 2017 Estimated Study Completion Date : May 2017 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Intravenous vitamin C injection During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer. Drug: Intravenous Nutrition (Vitamins) injection Other Name: Preoperative

2016 Clinical Trials

180. Safety of Intravenous Neridronic Acid in CRPS

is to investigate the safety of intravenous neridronic acid in patients with complex regional pain syndrome (CRPS). The trial is divided into 3 periods: a 60-day enrollment period, a treatment period consisting of 4 infusions over 10 days, and a follow-up period of approximately 50 weeks (with visits at Week 2, Week 6, Week 12, Week 26, Week 39, and Week 52). Condition or disease Intervention/treatment Phase Complex Regional Pain Syndrome Drug: Neridronic acid Phase 3 Study Design Go to Layout table for study (...) of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Neridronic acid Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg. Drug: Neridronic acid Neridronic acid administered as intravenous infusion. Outcome Measures Go to Primary Outcome Measures : Occurrence of any treatment emergent adverse event [ Time Frame: Day 1 to Week 52 ] The primary endpoint of this trial is a binary

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>